Samantha McLemore - Patient Capital Management,
Holding/activity history for Royalty Pharma plc (RPRX)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 3,643,716 | 6.52 | Add 9.30% | 0.55 | $47.97 | $174,789,053 | SEC |
| 2025 Q4 | 3,333,675 | 4.97 | Add 6.92% | 0.32 | $38.64 | $128,813,194 | SEC |
| 2025 Q3 | 3,117,850 | 4.40 | Add 4.35% | 0.18 | $35.28 | $109,997,741 | SEC |
| 2025 Q2 | 2,987,988 | 4.86 | Add 0.52% | 0.03 | $36.03 | $107,657,202 | SEC |
| 2025 Q1 | 2,972,646 | 4.76 | Add 3.39% | 0.16 | $31.13 | $92,538,459 | SEC |
| 2024 Q4 | 2,875,089 | 3.38 | Add 40.85% | 0.98 | $25.51 | $73,343,527 | SEC |
| 2024 Q3 | 2,041,195 | 2.84 | Add 43.30% | 0.86 | $28.29 | $57,745,414 | SEC |
| 2024 Q2 | 1,424,390 | 1.99 | Add 0.32% | <0.01 | $26.37 | $37,561,164 | SEC |
| 2024 Q1 | 1,419,818 | 2.10 | Add 13.15% | 0.24 | $30.37 | $43,119,875 | SEC |
| 2023 Q4 | 1,254,780 | 1.87 | Buy | 1.87 | $28.09 | $35,246,779 | SEC |